Recruiting Fibromyalgia Studies in Philadelphia
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
Plexiform neurofibromas (PN) are known to cause significant morbidity in children with NF1. The recent FDA approval for selumetinib in children 2 years and older with inoperable symptomatic PN was bas...
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagno...
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP). The study will evaluate how s...
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
The goal of this clinical trial is to learn about INS018\_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018\_055 orall...
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced β-cell mass contributes to the insulin secretory defects that char...
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
The trial will be an open label, single arm, phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with pr...
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
This is a Phase 1/2 multicenter, open-label, single dose trial of SP-101 investigational gene therapy in adults with CF who are ineligible for or intolerant to CFTR modulator therapy....
About Fibromyalgia Clinical Trials in Philadelphia
Fibromyalgia is a condition characterized by widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive difficulties. It affects about 2-4% of the population, predominantly women. Treatment includes medications, exercise, stress management, and cognitive behavioral therapy.
There are currently 7 fibromyalgia clinical trials recruiting participants in Philadelphia, PENNSYLVANIA. These studies are seeking a combined 515 participants. Research is being sponsored by University of Alabama at Birmingham, Incyte Corporation, Ashibio Inc and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Fibromyalgia Clinical Trials in Philadelphia — FAQ
Are there fibromyalgia clinical trials in Philadelphia?
Yes, there are 7 fibromyalgia clinical trials currently recruiting in Philadelphia, PENNSYLVANIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Philadelphia?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Philadelphia research site will contact you about next steps.
Are clinical trials in Philadelphia free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Philadelphia studies also compensate for your time and travel.
What fibromyalgia treatments are being tested?
The 7 active trials in Philadelphia are testing new therapies including novel drugs, biologics, and treatment approaches for fibromyalgia.
Data updated March 2, 2026 from ClinicalTrials.gov